AR120856A1 - Derivados de furoindazol - Google Patents
Derivados de furoindazolInfo
- Publication number
- AR120856A1 AR120856A1 ARP200103594A ARP200103594A AR120856A1 AR 120856 A1 AR120856 A1 AR 120856A1 AR P200103594 A ARP200103594 A AR P200103594A AR P200103594 A ARP200103594 A AR P200103594A AR 120856 A1 AR120856 A1 AR 120856A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- heteroaryl
- haloalkyl
- heterocycloalkyl
- Prior art date
Links
- LHTSYIHIIZNLCQ-UHFFFAOYSA-N 1h-furo[2,3-g]indazole Chemical class O1C=CC2=C1C=CC1=C2NN=C1 LHTSYIHIIZNLCQ-UHFFFAOYSA-N 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 15
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 150000002431 hydrogen Chemical group 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 4
- -1 C1−3-haloalkoxy Chemical group 0.000 abstract 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 3
- 229910052805 deuterium Inorganic materials 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000000643 heteroaryl-fused-heterocycloalkyl group Chemical group 0.000 abstract 3
- 230000002757 inflammatory effect Effects 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000017701 Endocrine disease Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 208000011623 Obstructive Lung disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 201000004982 autoimmune uveitis Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente cubre compuestos de furoindazol de fórmula general (1) en la cual R¹, R², R³, R⁴, R⁵, R⁶, R⁷ᵃ y R⁷ᵇ son como se define en la presente, métodos para preparar dichos compuestos, compuestos intermediarios útiles para preparar dichos compuestos, composiciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos para elaborar composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en particular de enfermedades autoinmunes tales como esclerosis múltiple, psoriasis, artritis psoriásica, artritis reumatoidea, espondilitis anquilosante, lupus eritematoso sistémico, uveítis autoinmune primaria y secundaria, trastornos inflamatorios como endometriosis, enfermedades oculares inflamatorias, enfermedades renales inflamatorias, enfermedades hepáticas inflamatorias como enfermedades hepáticas no alcohólicas, alcohólicas y de hígado graso tóxicas, enfermedades pulmonares como asma, fibrosis pulmonar idiopática, enfermedad pulmonar obstructiva crónica, y trastornos metabólicos y metabólico- endocrinos como síndrome metabólico, resistencia a la insulina, diabetes mellitus tipo I y tipo II, y trastornos de síndrome de ovario poliquístico (PCOS), trastornos de dolor neuropático e inflamatorio en humanos y animales. Reivindicación 1: Un compuesto de fórmula general (1) en la cual: R¹ representa hidrógeno, alquilo-C₁₋₄ o haloalquilo-C₁₋₄; R² representa hidrógeno, alquilo-C₁₋₄ o haloalquilo-C₁₋₄; o R¹ y R² junto con el átomo de carbono al cual están unidos forman un anillo cicloalquilo o heterocicloalquilo de 3 a 6 miembros; R³ representa cicloalquilo-C₃₋₆, heterocicloalquilo de 3 a 6 miembros, heterocicloalquilo fusionado con fenilo o heteroarilo, o heteroarilo, en donde dichos grupos están opcionalmente sustituidos, una o varias veces, independientemente entre sí, con R⁸, o R³ representa fenilo, que está opcionalmente sustituido, una o varias veces, independientemente entre sí, con R⁸, y adicionalmente R⁷ᵃ y R⁷ᵇ representan deuterio; R⁴ representa hidrógeno, alquilo-C₁₋₄, haloalquilo-C₁₋₄ o cicloalquilo-C₃₋₆; R⁵, R⁶ representan, independientemente entre sí, hidrógeno, alquilo-C₁₋₄, hidroxialquilo-C₂₋₄, (alcoxi-C₁₋₄)-(alquilo-C₂₋₄)-, cicloalquilo-C₃₋₆, haloalquilo-C₁₋₄, halocicloalquilo-C₃₋₆, heterocicloalquilo de 3 a 6 miembros, heteroespirocicloalquilo, fenilo, heteroarilo, heterocicloalquilo fusionado con fenilo o heteroarilo, heterocicloalquil-(alquilo-C₁₋₃) de 3 a 6 miembros, heteroespirocicloalquil-(alquilo-C₁₋₃), (heterocicloalquilo fusionado con fenilo o heteroaril)-(alquilo-C₁₋₃)-, fenil-(alquilo-C₁₋₃)- o heteroaril-(alquilo-C₁₋₃)-, en donde dichos grupos heterocicloalquilo de 3 a 6 miembros, heteroespirocicloalquilo, heterocicloalquilo fusionado con fenilo o heteroarilo, fenilo o heteroarilo están opcionalmente sustituidos, una o varias veces, independientemente entre sí, con R⁹, o R⁵ y R⁶ junto con el átomo de nitrógeno al cual están unidos forman un anillo heterocíclico de 3 a 6 miembros que contiene nitrógeno, que opcionalmente contiene un heteroátomo o grupo que contiene heteroátomo adicional seleccionado de O, NH y S, y que puede estar opcionalmente sustituido, una o varias veces, independientemente entre sí, con R⁹; R⁷ᵃ representa hidrógeno, deuterio o alquilo-C₁₋₄; R⁷ᵇ representa hidrógeno, deuterio o alquilo-C₁₋₄; R⁸ representa halógeno, ciano, alquilo-C₁₋₄, haloalquilo-C₁₋₄, alcoxi-C₁₋₃, haloalcoxi-C₁₋₃, cicloalquilo-C₃₋₆, cicloalquil-C₃₋₆-(alquilo-C₁₋₃)-, R¹³-(C=O)-, R¹⁰-O-(C=O)-, R¹¹-NH-(C=O)- o R¹²-(SO₂)-; R⁹ representa halógeno, ciano, alquilo-C₁₋₄, haloalquilo-C₁₋₄, H₂N-alquilo-C₁₋₄, alcoxi-C₁₋₃, haloalcoxi-C₁₋₃, cicloalquilo-C₃₋₆, R¹⁰-O-(C=O)-, oxo, heterocicloalquilo- de 5 a 6 miembros, heterocicloalquil-(alquilo-C₁₋₃)- de 5 a 6 miembros, fenilo o heteroarilo, en donde dicho grupo fenilo o heteroarilo está opcionalmente sustituido, una o varias veces, independientemente entre sí, con halógeno, alquilo-C₁₋₄, haloalquilo-C₁₋₄, alcoxi-C₁₋₃ o haloalcoxi-C₁₋₃; R¹⁰ representa hidrógeno, alquilo-C₁₋₄ o fenilo-CH₂-; R¹¹ representa hidrógeno, alquilo-C₁₋₄, o heterocicloalquil-(alquilo-C₁₋₃)- de 5 a 6 miembros; R¹² representa alquilo-C₁₋₄ o fenilo; R¹³ representa alquilo-C₁₋₄, haloalquilo-C₁₋₄, (alcoxi-C₁₋₄)-(alquilo-C₁₋₄)-, alquilo-C₁₋₄-(C=O)-, cicloalquilo-C₃₋₆ o fenilo, en donde dicho grupo cicloalquilo-C₃₋₆ está opcionalmente sustituido con alquilo-C₁₋₄ o hidroxi y dicho grupo fenilo está opcionalmente sustituido, una o varias veces, independientemente entre sí, con halógeno, alquilo-C₁₋₄, haloalquilo-C₁₋₄, alcoxi-C₁₋₃ o haloalcoxi-C₁₋₃; o un estereoisómero, un tautómero, un N-óxido, un hidrato, un solvato o una sal de dicho compuesto, o una mezcla de ellos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19217856 | 2019-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120856A1 true AR120856A1 (es) | 2022-03-23 |
Family
ID=68965797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103594A AR120856A1 (es) | 2019-12-19 | 2020-12-21 | Derivados de furoindazol |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230112499A1 (es) |
| EP (1) | EP4077334A1 (es) |
| JP (1) | JP2023508908A (es) |
| KR (1) | KR20220118480A (es) |
| CN (1) | CN115135656B (es) |
| AR (1) | AR120856A1 (es) |
| AU (1) | AU2020408908A1 (es) |
| BR (1) | BR112022011237A2 (es) |
| CA (1) | CA3164963A1 (es) |
| CL (1) | CL2022001644A1 (es) |
| CO (1) | CO2022008338A2 (es) |
| CR (1) | CR20220291A (es) |
| DO (1) | DOP2022000126A (es) |
| EC (1) | ECSP22047527A (es) |
| GE (1) | GEP20247585B (es) |
| IL (1) | IL293968A (es) |
| JO (1) | JOP20220156A1 (es) |
| MX (1) | MX2022007685A (es) |
| PE (1) | PE20221786A1 (es) |
| TW (1) | TW202136271A (es) |
| WO (1) | WO2021122415A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118638043A (zh) | 2019-12-19 | 2024-09-13 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| EP4298102A1 (en) * | 2021-02-23 | 2024-01-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
| WO2022194267A1 (zh) * | 2021-03-18 | 2022-09-22 | 武汉人福创新药物研发中心有限公司 | 一种gpr84拮抗剂及其制备方法和用途 |
| WO2022229061A1 (en) * | 2021-04-29 | 2022-11-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
| WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
| WO2024140969A1 (zh) * | 2022-12-30 | 2024-07-04 | 广州市联瑞制药有限公司 | 三环类化合物及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT853083E (pt) | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| AU727654B2 (en) | 1997-06-13 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrazole derivative |
| WO2001083487A1 (fr) | 2000-04-28 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de froindazole |
| WO2009023773A2 (en) * | 2007-08-15 | 2009-02-19 | University Of Miami | Galactokinase inhibitors |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| US8263610B2 (en) | 2008-12-30 | 2012-09-11 | Arqule, Inc. | Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds |
| WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| WO2014095798A1 (en) * | 2012-12-20 | 2014-06-26 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
| GB201411241D0 (en) | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2016085990A1 (en) * | 2014-11-24 | 2016-06-02 | The Regents Of The University Of Michigan | Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity |
| GB201506894D0 (en) | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CN108530480B (zh) | 2017-03-06 | 2022-06-28 | 中国科学院上海药物研究所 | Gpr84受体拮抗剂及其应用 |
| US20210177827A1 (en) | 2017-10-25 | 2021-06-17 | Children`S Medical Center Corporation | Papd5 inhibitors and methods of use thereof |
-
2020
- 2020-12-14 CA CA3164963A patent/CA3164963A1/en active Pending
- 2020-12-14 TW TW109144136A patent/TW202136271A/zh unknown
- 2020-12-14 IL IL293968A patent/IL293968A/en unknown
- 2020-12-14 PE PE2022001093A patent/PE20221786A1/es unknown
- 2020-12-14 EP EP20823813.9A patent/EP4077334A1/en active Pending
- 2020-12-14 US US17/786,268 patent/US20230112499A1/en active Pending
- 2020-12-14 AU AU2020408908A patent/AU2020408908A1/en active Pending
- 2020-12-14 MX MX2022007685A patent/MX2022007685A/es unknown
- 2020-12-14 BR BR112022011237A patent/BR112022011237A2/pt unknown
- 2020-12-14 WO PCT/EP2020/085905 patent/WO2021122415A1/en active Application Filing
- 2020-12-14 JO JOP/2022/0156A patent/JOP20220156A1/ar unknown
- 2020-12-14 CR CR20220291A patent/CR20220291A/es unknown
- 2020-12-14 KR KR1020227024304A patent/KR20220118480A/ko unknown
- 2020-12-14 JP JP2022537545A patent/JP2023508908A/ja active Pending
- 2020-12-14 CN CN202080097024.7A patent/CN115135656B/zh active Active
- 2020-12-14 GE GEAP202016005A patent/GEP20247585B/en unknown
- 2020-12-21 AR ARP200103594A patent/AR120856A1/es unknown
-
2022
- 2022-06-14 EC ECSENADI202247527A patent/ECSP22047527A/es unknown
- 2022-06-15 CO CONC2022/0008338A patent/CO2022008338A2/es unknown
- 2022-06-15 DO DO2022000126A patent/DOP2022000126A/es unknown
- 2022-06-16 CL CL2022001644A patent/CL2022001644A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115135656A (zh) | 2022-09-30 |
| CN115135656B (zh) | 2024-06-14 |
| KR20220118480A (ko) | 2022-08-25 |
| CL2022001644A1 (es) | 2023-02-24 |
| EP4077334A1 (en) | 2022-10-26 |
| WO2021122415A9 (en) | 2022-06-30 |
| GEP20247585B (en) | 2024-01-25 |
| ECSP22047527A (es) | 2022-07-29 |
| JP2023508908A (ja) | 2023-03-06 |
| CR20220291A (es) | 2022-08-10 |
| CA3164963A1 (en) | 2021-06-24 |
| US20230112499A1 (en) | 2023-04-13 |
| MX2022007685A (es) | 2022-07-19 |
| PE20221786A1 (es) | 2022-11-22 |
| DOP2022000126A (es) | 2022-07-15 |
| CO2022008338A2 (es) | 2022-07-08 |
| AU2020408908A1 (en) | 2022-06-30 |
| WO2021122415A1 (en) | 2021-06-24 |
| TW202136271A (zh) | 2021-10-01 |
| JOP20220156A1 (ar) | 2023-01-30 |
| BR112022011237A2 (pt) | 2022-08-30 |
| IL293968A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120856A1 (es) | Derivados de furoindazol | |
| ES2969868T3 (es) | Antagonistas selectivos de P2X3 para su uso en el tratamiento de la tos crónica sin pérdida de la respuesta gustativa | |
| AR107795A1 (es) | Indazoles 2-sustituidos, procedimientos para su preparación, y su uso para la preparación de medicamentos | |
| PE20220143A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| NI201800080A (es) | Derivados de pirazolo[1, 5-a]pirazin-4-ilo como inhibidores de jak | |
| PE20190607A1 (es) | Estimuladores de sgc | |
| AR040351A1 (es) | Derivados de quinuclidina-amida, composicion farmaceutica, procedimiento de preparacion del compuesto y su uso para fabricar medicamentos | |
| AR121929A1 (es) | AMINOTIAZOLES SUSTITUIDOS COMO INHIBIDORES DE DGKz PARA LA ACTIVACIÓN INMUNE | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR067412A1 (es) | Moduladores de propiedades farmaceuticas de productos terapeuticos | |
| EA201690515A1 (ru) | Производные диазокарбазола в качестве пэт-лигандов белка tau | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| PE20241476A1 (es) | Inhibidores de la ras | |
| AR053435A1 (es) | Derivados de 5-amminoindol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un madicamento para el tratamiento de enfermedades asociadas a la modulacion de receptores h3. | |
| JP2015523385A5 (es) | ||
| RU2016119662A (ru) | ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc | |
| MX2022006470A (es) | Tiromimeticos novedosos. | |
| AR096041A1 (es) | Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg | |
| AR044906A1 (es) | Derivados de difenilpiridina, su preparacion y su aplicacion en terapeutica | |
| BR112017001516A2 (pt) | método de ressolubilização quiral, estereoisômero, método para preparar um composto, composto, composição, e kit de ressolubilização quiral | |
| MX2016003422A (es) | Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen. | |
| EA202092815A1 (ru) | Новый стабилизатор длительного действия для резины и резиновая смесь для шин, содержащая указанный стабилизатор | |
| AR071619A1 (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen. | |
| AR103254A1 (es) | Profármacos de creatina, composiciones y métodos de uso de estos | |
| AR094412A1 (es) | Carboxamidas basadas en pirazolilo i |